Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:50746
Name mantle cell lymphoma
Definition A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma mantle cell lymphoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
RB1 wild-type TP53 mut R547 mantle cell lymphoma sensitive detail...
RB1 wild-type TP53 wild-type R547 mantle cell lymphoma sensitive detail...
ATM inact mut Olaparib mantle cell lymphoma sensitive detail...
ATM inact mut Bendamustine + Olaparib mantle cell lymphoma sensitive detail...
ATM inact mut Olaparib + Valproic acid mantle cell lymphoma sensitive detail...
ATM inact mut Fludarabine + Olaparib mantle cell lymphoma sensitive detail...
TP53 loss Bendamustine + Rituximab mantle cell lymphoma no benefit detail...
TP53 loss Ibrutinib + Rituximab mantle cell lymphoma predicted - sensitive detail...
TP53 G244S Ibrutinib + Rituximab mantle cell lymphoma predicted - sensitive detail...
ATM mutant Ibrutinib + Venetoclax mantle cell lymphoma predicted - sensitive detail...
SMARCA4 mutant Ibrutinib + Venetoclax mantle cell lymphoma predicted - resistant detail...
NRAS G13D ERAS-007 mantle cell lymphoma sensitive detail...
NRAS G13D Copanlisib + ERAS-007 mantle cell lymphoma sensitive detail...
ATM R2832C RP-3500 mantle cell lymphoma sensitive detail...
ATM R2832C Niraparib + RP-3500 mantle cell lymphoma sensitive detail...
ATM dec exp ATM inact mut ART0380 mantle cell lymphoma predicted - sensitive detail...
TP53 mutant N/A mantle cell lymphoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00114738 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate Rituximab Bortezomib EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma Completed USA 0
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed USA 0
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated USA 0
NCT00878254 Phase II Cyclophosphamide + Cytarabine + Doxorubicin + Etoposide + Filgrastim + Ifosfamide + Leucovorin + Mesna + Methotrexate + Rituximab + Vincristine Sulfate Rituximab Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma Active, not recruiting USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Terminated USA 0
NCT01111188 Phase I Bortezomib + Palbociclib Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma Terminated USA 0
NCT01180049 FDA approved Temsirolimus Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Completed USA | ROU | POL | ITA | FRA | DEU | CZE | AUS 3
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed USA | DNK 0
NCT01267812 Phase II Bortezomib + Rituximab Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation Completed USA 0
NCT01415752 Phase II Bortezomib Bendamustine Rituximab Lenalidomide Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma Active, not recruiting USA | CAN 0
NCT01439750 Phase Ib/II Bortezomib + Cladribine + Rituximab Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) Unknown status USA 0
NCT01686165 Phase II Belinostat Rituximab Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Completed USA 0
NCT01695941 Phase I Alisertib + Bortezomib + Rituximab Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT01719250 Phase I Buparlisib Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed USA 0
NCT01796171 Phase Ib/II Lilotomab Betalutin Rituximab A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) Completed USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BEL | AUT | AUS 2
NCT01799889 Phase II Entospletinib A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies Terminated USA | CAN 0
NCT01804686 Phase III Ibrutinib A Long-term Extension Study of PCI-32765 (Ibrutinib) Recruiting USA | TUR | SWE | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG 10
NCT01811368 Phase II anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Unknown status USA 0
NCT01880567 Phase II Ibrutinib + Rituximab Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma Active, not recruiting USA 0
NCT01897012 Phase I Romidepsin Alisertib Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Completed USA 0
NCT01905813 Phase I Dezapelisib + Itacitinib Dezapelisib Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting USA 0
NCT01955499 Phase I Ibrutinib + Lenalidomide Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Active, not recruiting USA | CAN 0
NCT01994382 Phase I Cerdulatinib Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma Completed USA 0
NCT02000934 Phase I Mivavotinib A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Completed USA | ITA | GBR | ESP 0
NCT02018861 Phase I Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies Completed USA 0
NCT02049541 Phase I Buparlisib + Rituximab Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma Completed USA 0
NCT02106091 Phase I AFM11 Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL Terminated USA | POL | DEU | CZE 0
NCT02159755 Phase I Ibrutinib + Palbociclib Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma Active, not recruiting USA 0
NCT02203903 Phase I MultiTAA-specific T cells Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) Recruiting USA 0
NCT02208037 Phase II Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed USA 0
NCT02213926 Phase II Acalabrutinib An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma Active, not recruiting USA | POL | NLD | ITA | GBR | FRA | ESP | CZE | BEL | AUS 0
NCT02242097 Phase II Ibrutinib Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma Active, not recruiting USA 0
NCT02268851 Phase I Ibrutinib + Umbralisib A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL Completed USA 0
NCT02269085 Phase Ib/II Carfilzomib + Ibrutinib A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma Terminated USA 0
NCT02285244 Phase II Sotrastaurin Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation Withdrawn 0
NCT02303392 Phase I Ibrutinib + Selinexor Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma Unknown status USA 0
NCT02328014 Phase Ib/II ACP-319 Acalabrutinib ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies Active, not recruiting USA 0
NCT02339922 Phase II Ixazomib + Rituximab Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT02381080 Phase I Erythromycin + Ibrutinib + Voriconazole Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy Completed ESP | CAN 1
NCT02419560 Phase I Ibrutinib + Venetoclax Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL Completed USA 0
NCT02420795 Phase Ib/II ONC201 Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Terminated USA 0
NCT02427620 Phase II Cyclophosphamide + Doxorubicin + Vincristine Sulfate Filgrastim Dexamethasone Cytarabine + Methotrexate Leucovorin A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma Active, not recruiting USA 0
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated USA | ARG 0
NCT02446236 Phase I Ibrutinib + Lenalidomide + Rituximab Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL) Active, not recruiting USA 0
NCT02454270 Phase II JNJ-64052781 A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies Terminated USA | ISR | FRA | ESP | BEL 0
NCT02455297 Phase II Copanlisib Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) Terminated USA 0
NCT02457598 Phase I Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Terminated USA | GBR | FRA 0
NCT02489123 Phase I Enzalutamide Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Terminated USA 0
NCT02564744 Phase II Naratuximab emtansine + Rituximab Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL Completed USA | POL | ITA | HUN | CZE | CHE | BGR | BEL 1
NCT02572453 Phase II Onalespib Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL) Terminated USA 0
NCT02601313 Phase II axicabtagene ciloleucel + Cyclophosphamide + Fludarabine A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) Completed USA | NLD | FRA | DEU 0
NCT02603445 Phase I BCL201 + Idelalisib Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL Completed USA | FRA | DEU | AUT 0
NCT02631044 Phase I Lisocabtagene maraleucel Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Completed USA 0
NCT02632396 Phase Ib/II Ixazomib + Rituximab Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission Active, not recruiting USA 0
NCT02650999 Phase Ib/II Pembrolizumab Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas Completed USA 0
NCT02706392 Phase I Cyclophosphamide + Fludarabine + ROR1 CAR-T cells Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies Terminated USA 0
NCT02717624 Phase I Acalabrutinib + Bendamustine + Rituximab A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma Active, not recruiting USA | POL | ITA 0
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Active, not recruiting USA 0
NCT02736617 Phase II Ibrutinib + Obinutuzumab Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma Completed USA 0
NCT02743546 Phase I Ibrutinib + JNJ-64052781 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma Withdrawn 0
NCT02745769 Phase I Merestinib + Ramucirumab Abemaciclib + Ramucirumab A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents Completed USA | GBR | FRA 0
NCT02756247 Phase I Buparlisib + Ibrutinib A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma Completed USA 0
NCT02776813 Phase I ACTR087 + Rituximab Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma Completed USA 0
NCT02797470 Phase Ib/II Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Active, not recruiting USA 0
NCT02858258 Phase III Cisplatin + Cytarabine + Dexamethasone + Filgrastim + Rituximab Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma Recruiting SWE | NOR | ITA | DNK | DEU 0
NCT02869633 Phase II Ibrutinib Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant Completed USA 0
NCT02875002 Phase I Belinostat + Volasertib Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas Withdrawn USA 0
NCT02900716 Phase I DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas Completed USA 0
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Terminated USA 0
NCT02950220 Phase I Ibrutinib + Pembrolizumab Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed USA 0
NCT02972840 Phase III Bendamustine + Rituximab Acalabrutinib + Bendamustine + Rituximab A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma Active, not recruiting USA | ROU | POL | NZL | ITA | ISR | HUN | GRC | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG 10
NCT03010358 Phase Ib/II Entospletinib + Obinutuzumab Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Completed USA 0
NCT03015896 Phase Ib/II Lenalidomide + Nivolumab Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Active, not recruiting USA 0
NCT03019640 Phase II Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma Completed USA 0
NCT03028103 Phase I Fluconazole + Tazemetostat Omeprazole + Repaglinide + Tazemetostat Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects Completed USA 0
NCT03037645 Phase Ib/II Vecabrutinib Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers Terminated USA 0
NCT03088878 Phase Ib/II Cirmtuzumab Cirmtuzumab + Ibrutinib Ibrutinib A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Completed USA 0
NCT03112174 Phase III Ibrutinib Ibrutinib + Venetoclax Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) Completed USA | TUR | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS 2
NCT03147885 Phase Ib/II Selinexor Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT03153202 Phase Ib/II Ibrutinib + Pembrolizumab Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) Active, not recruiting USA 0
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Active, not recruiting USA 0
NCT03188965 Phase I Elimusertib First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Completed USA | GBR | CHE | CAN 3
NCT03189836 Phase I ACTR707 + Rituximab Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma Terminated USA 0
NCT03219047 Phase I Ibrutinib The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response Completed USA 0
NCT03232307 Phase II Ibrutinib + Lenalidomide + Rituximab Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL) Withdrawn 0
NCT03235544 Phase II Parsaclisib A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) Completed USA | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CZE | BEL 0
NCT03267433 Phase III Rituximab Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Active, not recruiting USA 1
NCT03277729 Phase Ib/II CD20 CAR-T cells + Cyclophosphamide + Fludarabine A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Active, not recruiting USA 0
NCT03282396 Phase II Ibrutinib Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma Active, not recruiting USA 0
NCT03311126 Phase II Bendamustine + Obinutuzumab Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma Terminated USA 0
NCT03323151 Phase Ib/II Ibrutinib + Ixazomib A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma (PrE0404) Completed USA 0
NCT03379493 Phase I Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma Terminated USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Terminated USA | FRA | ESP | DEU | CHE 1
NCT03424122 Phase I Ibrutinib + Parsaclisib Bendamustine + Parsaclisib + Rituximab Parsaclisib + Rituximab INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Completed USA | ITA | ESP 0
NCT03424603 Phase I STRO-001 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Completed USA 0
NCT03440567 Phase I Avelumab + Carboplatin + Etoposide + Ifosfamide + Rituximab + Utomilumab Avelumab + Ibrutinib + Rituximab + Utomilumab Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Active, not recruiting USA 0
NCT03478514 Phase II Ibrutinib + Palbociclib Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma Active, not recruiting USA 0
NCT03479268 Phase I Ibrutinib + MLN4924 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT03523975 Phase I Lenalidomide + Rituximab + Venetoclax Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Recruiting USA 0
NCT03537482 Phase I APG-2575 APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies Recruiting USA | AUS 0
NCT03547115 Phase I Voruciclib A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies Recruiting USA 0
NCT03557619 Phase I Ethinylestradiol + Levonorgestrel + Venetoclax A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies Recruiting USA | AUS 0
NCT03571568 Phase Ib/II BI-1206 + Rituximab A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Recruiting USA | SWE | POL | ESP | DEU | BRA 0
NCT03571828 Phase I AMG562 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma Terminated USA | DEU | CAN | BEL 0
NCT03579927 Phase Ib/II Filgrastim iC9-CAR.19-IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Withdrawn USA 0
NCT03585725 Phase I Ribavirin A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Terminated USA 0
NCT03601819 Phase I Pacritinib Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Terminated USA 0
NCT03617484 Phase II Bortezomib + Ibrutinib Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma Withdrawn USA 0
NCT03623373 Phase II Acalabrutinib + Bendamustine + Cytarabine + Rituximab Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Active, not recruiting USA 0
NCT03625037 Phase Ib/II Epcoritamab-bysp First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1) Active, not recruiting USA | SWE | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUS 2
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT03682796 Phase I TRPH-222 Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Completed USA | CAN 0
NCT03684694 Phase I Ibrutinib + Loncastuximab tesirine-lpyl Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma Terminated USA | ITA | GBR | FRA | ESP | BEL 0
NCT03685344 Phase I Durvalumab + Loncastuximab tesirine-lpyl Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma Terminated USA | ESP 0
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Recruiting USA 0
NCT03710772 Phase II Ibrutinib + Rituximab + Venetoclax Cyclophosphamide + Dexamethasone + Doxorubicin + Rituximab + Vincristine Sulfate Cytarabine + Methotrexate + Rituximab Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Active, not recruiting USA 0
NCT03740529 Phase Ib/II Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Active, not recruiting USA | SWE | POL | ITA | GBR | FRA | CHE | AUS 2
NCT03755154 Phase I VOB560 Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia Terminated GBR | FRA | ESP | AUS 0
NCT03765177 Phase Ib/II CLIC-1901 CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01) Recruiting CAN 0
NCT03779113 Phase Ib/II HMPL-523 An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma Active, not recruiting USA | POL | ITA | FRA | FIN | ESP | DNK 0
NCT03786926 Phase Ib/II HMPL-689 Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas Active, not recruiting USA | POL | ITA | FRA | FIN | ESP 0
NCT03833180 Phase I VLS-101 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies Completed USA 0
NCT03834688 Phase II Bendamustine + Rituximab + Venetoclax Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age (PrE0405) Completed USA 0
NCT03863184 Phase II Acalabrutinib + Lenalidomide + Rituximab Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL Active, not recruiting USA 0
NCT03872180 Phase II Bendamustine + Obinutuzumab + Venetoclax Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma Active, not recruiting USA 0
NCT03877055 Phase Ib/II Copanlisib + Ibrutinib Ibrutinib A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma Completed USA 0
NCT03886831 Phase I PRT543 A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Completed USA 0
NCT03920631 Phase I Nivolumab Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) Withdrawn USA 0
NCT03939182 Phase Ib/II Abexinostat + Ibrutinib Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma Active, not recruiting USA 0
NCT03946878 Phase II Acalabrutinib + Venetoclax Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Active, not recruiting USA 0
NCT03997968 Phase Ib/II CYT01B A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Active, not recruiting USA 0
NCT04002297 Phase III Rituximab + Zanubrutinib Bendamustine + Rituximab Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Patients With Untreated Mantle Cell Lymphoma Active, not recruiting USA | TUR | ROU | POL | NZL | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 6
NCT04007029 Phase I Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Recruiting USA 0
NCT04014205 Phase I Orelabrutinib A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies Active, not recruiting USA | POL | ISR 1
NCT04043845 Phase I Ibrutinib + LY3214996 ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies Withdrawn 0
NCT04047797 Phase II Ixazomib + Rituximab Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Active, not recruiting USA 0
NCT04052854 Expanded access Zanubrutinib A Single-Arm, Expanded Access Study of Zanubrutinib (BGB3111) in Patients With B-cell Malignancies No longer available USA 0
NCT04072458 Phase I BP1002 A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies Recruiting USA 0
NCT04074330 Phase Ib/II Rituximab + Subasumstat A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN 2
NCT04082936 Phase I IGM-2323 A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Terminated USA | ITA | FRA | ESP | CZE | AUS 1
NCT04115631 Phase II Acalabrutinib + Bendamustine + Rituximab Bendamustine + Cytarabine + Rituximab Acalabrutinib + Bendamustine + Cytarabine + Rituximab A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma Active, not recruiting USA 0
NCT04136275 Phase I Anti-CD37 CAR T cells CAR-37 T Cells In Hematologic Malignancies Completed USA 0
NCT04160195 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Terminated USA 0
NCT04162756 Expanded access Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Study of KTE-X19 for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies (ZUMA-18) Approved for marketing USA 0
NCT04189757 Phase II Acalabrutinib Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma Active, not recruiting USA 0
NCT04223765 Phase I Bendamustine + CAR.k.28 cells + Fludarabine CAR.k.28 cells + Cyclophosphamide + Fludarabine Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma Recruiting USA 0
NCT04277637 Phase I BGB-11417 + Zanubrutinib BGB-11417 Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies Recruiting USA | NZL | ITA | GBR | ESP | DEU | AUS 0
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Completed AUS 1
NCT04283097 Phase I KPG-818 Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects Recruiting USA 0
NCT04401020 Phase I SAR442257 First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL Active, not recruiting USA | NOR | ESP | CZE 1
NCT04402138 Phase II Acalabrutinib Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma Completed USA 0
NCT04419389 Phase Ib/II Acalabrutinib + APR-246 APR-246 + Rituximab + Venetoclax APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) Terminated USA 0
NCT04484012 Phase II Acalabrutinib + CD19R(EQ)28zetaEGFRt+ Tn/mem cells Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Recruiting USA 0
NCT04491370 Phase Ib/II Polatuzumab vedotin-piiq Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma Recruiting USA 0
NCT04540796 Phase I JNJ-75348780 A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Active, not recruiting USA | ISR | GBR | FRA | ESP | AUS 2
NCT04545762 Phase I Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Recruiting USA 0
NCT04566887 Phase II Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma Active, not recruiting CAN 0
NCT04578600 Phase I Azacitidine + Lenalidomide + Obinutuzumab CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Active, not recruiting USA 0
NCT04594642 Phase I TNB-486 A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Recruiting USA | AUS 3
NCT04599634 Phase I Hu5F9-G4 + Obinutuzumab + Venetoclax Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies Completed USA 0
NCT04626791 Phase II Acalabrutinib + Cytarabine + Rituximab Hyaluronidase Acalabrutinib + Cytarabine + Rituximab Acalabrutinib + Bortezomib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Acalabrutinib + Bortezomib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Hyaluronidase Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma Recruiting USA 0
NCT04635683 Phase I Lenalidomide + Ublituximab + Umbralisib Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Withdrawn 0
NCT04640779 Phase I Choline salicylate + Selinexor Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients With Residual, Relapsed or Refractory Non-Hodgkin Lymphoma Recruiting USA 0
NCT04659044 Phase II Polatuzumab vedotin-piiq + Rituximab + Rituximab Hyaluronidase + Venetoclax Rituximab Hyaluronidase + Venetoclax Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Terminated USA 0
NCT04662255 Phase III Ibrutinib Zanubrutinib Pirtobrutinib Acalabrutinib Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321) Active, not recruiting USA | POL | NZL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS 6
NCT04665115 Phase II Ibrutinib Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) Withdrawn USA 0
NCT04684563 Phase I HuCART19-IL18 huCART19-IL18 in NHL/CLL Patients Recruiting USA 0
NCT04692155 Phase Ib/II Cyclophosphamide + Doxorubicin + Prednisone + Ublituximab + Umbralisib + Vincristine Sulfate Phase Ib/II Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL) (CHOP U2) Terminated USA 0
NCT04703686 Phase II Glofitamab-gxbm + Obinutuzumab Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy Active, not recruiting FRA 0
NCT04728893 Phase II ARQ 531 Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) Recruiting USA | TUR | ROU | POL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUS | ARG 3
NCT04763083 Phase Ib/II NVG-111 First in Human Study of NVG-111 in Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma Recruiting GBR 0
NCT04765111 Phase II Acalabrutinib + Rituximab Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma Active, not recruiting USA 0
NCT04771572 Phase I LP-118 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. Recruiting USA 0
NCT04783415 Phase II Acalabrutinib + Ublituximab + Umbralisib Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma Active, not recruiting USA 0
NCT04802590 Phase II Ibrutinib Ibrutinib + Venetoclax Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma Recruiting GBR | FRA | BEL 0
NCT04809467 Phase Ib/II Parsaclisib + Tafasitamab-cxix A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) Completed USA | ITA | FRA | ESP | DEU | BEL | AUT 0
NCT04830137 Phase I NX-2127 A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting USA 0
NCT04836195 Phase I PCLX-001 Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma Recruiting CAN 0
NCT04842877 Phase II DS-3201b Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma Active, not recruiting FRA | BEL 0
NCT04853329 Phase Ib/II CPO107 Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma Suspended USA 0
NCT04855695 Phase Ib/II Acalabrutinib + Obinutuzumab + Venetoclax Avo In R/R And Previously Untreated MCL Recruiting USA 0
NCT04861779 Phase I HSK29116 A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies Unknown status AUS 1
NCT04880434 Phase II Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Active, not recruiting USA | NLD | GBR | FRA | ESP | DEU 0
NCT04883437 Phase II Acalabrutinib + Obinutuzumab Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Recruiting USA 0
NCT04903197 Phase I Lenalidomide + VAY736 VAY736 Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma Active, not recruiting ITA | DEU | AUS 4
NCT04913103 Phase II Bendamustine + Polatuzumab vedotin-piiq + Rituximab Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL (CLSGMCLPOLA) Not yet recruiting CZE 0
NCT04939272 Phase Ib/II Copanlisib + Venetoclax Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Active, not recruiting USA 0
NCT04975555 Phase II Siltuximab Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Recruiting USA 0
NCT04990778 Phase II APR-246 + Venetoclax Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma Withdrawn USA 0
NCT05003141 Phase I PSB202 PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies Unknown status USA | AUS 1
NCT05006716 Phase I BGB-16673 A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies Recruiting USA | TUR | SWE | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS 3
NCT05008055 Phase II Capivasertib Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL) Active, not recruiting USA | GBR | FRA | ESP | DNK | CAN 1
NCT05020678 Phase I Cyclophosphamide + Fludarabine NKX019 NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Recruiting USA | AUS 0
NCT05025423 Phase II Rituximab + Venetoclax Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma Recruiting USA 0
NCT05025800 Phase Ib/II Evorpacept + Lenalidomide + Rituximab ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT05053659 Phase I Loncastuximab tesirine-lpyl + Venetoclax Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma Recruiting USA 0
NCT05065866 Phase I Azacitidine + Duvelisib Duvelisib in Combination With CC-486 in Lymphoid Malignancy Active, not recruiting USA 0
NCT05131022 Phase I NX-5948 Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting USA | NLD | GBR 0
NCT05144347 Phase I XL114 Study of XL114 in Subjects With Non-Hodgkin's Lymphoma Terminated USA 0
NCT05172700 Expanded access Pirtobrutinib Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer Available 0
NCT05205161 Phase Ib/II AZD0466 A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma Terminated USA | ITA | FRA | ESP | AUS 2
NCT05205252 Phase Ib/II Lenalidomide + Tafasitamab-cxix + Tazemetostat Daratumumab + Dexamethasone + Pomalidomide + Tazemetostat Daratumumab and hyaluronidase-fihj + Dexamethasone + Pomalidomide + Tazemetostat Mosunetuzumab-axgb + Tazemetostat Lenalidomide + Tazemetostat Acalabrutinib + Tazemetostat A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. (ARIA) Withdrawn USA 0
NCT05207670 Phase II Mosunetuzumab-axgb + Tocilizumab A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) Active, not recruiting USA 0
NCT05211336 Phase I Lenalidomide + Nivolumab Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System Active, not recruiting USA 0
NCT05249959 Phase II Bendamustine + Cytarabine + Rituximab Loncastuximab tesirine-lpyl Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (FIL_COLUMN) Recruiting ITA 0
NCT05260957 Phase II Mosunetuzumab-axgb + Polatuzumab vedotin-piiq CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). Recruiting USA 0
NCT05279300 Phase I CS5001 A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas Recruiting USA | AUS 1
NCT05346809 Phase II Isatuximab Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma Recruiting USA 0
NCT05348889 Phase Ib/II 1A46 First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies Recruiting USA 0
NCT05360238 Phase Ib/II MB-106 Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL Terminated USA 0
NCT05365659 Phase I IKS03 IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Recruiting USA | ITA | ESP | CAN | AUS 0
NCT05370430 Phase I BAFFR-CAR T cells BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL Recruiting USA 0
NCT05424822 Phase I JNJ-80948543 A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting USA | POL | ISR | FRA | DNK | AUS 2
NCT05458297 Phase II VLS-101 ARQ 531 + VLS-101 A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination With Nemtabrutinib (MK-1026) in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) Recruiting USA | TUR | SWE | POL | ITA | ISR | IRL | GBR | EST | ESP | DEU | CZE | CAN | BRA 7
NCT05471843 Phase II BGB-11417 Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma Active, not recruiting USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | BRA | BEL | ARG 2
NCT05495464 Phase I Cyclophosphamide + Fludarabine Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Acalabrutinib + Rituximab A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma Recruiting USA 0
NCT05529069 Phase II Pirtobrutinib + Venetoclax Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients Recruiting USA 0
NCT05564052 Phase II Ibrutinib + Rituximab Bortezomib + Lenalidomide + Rituximab A Study of Ibrutinib With Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (VEGA) Completed TUR | SWE | ROU | POL | GRC | ESP | CZE | BRA 5
NCT05588440 Phase Ib/II Cyclophosphamide + Fludarabine ONCT-808 A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies Terminated USA 0
NCT05602363 Phase I AS-1763 AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma Recruiting USA 0
NCT05635162 Phase II Rituximab + Zanubrutinib Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma (ZEBRA) Recruiting GBR 0
NCT05659732 Phase I PEP07 A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer Recruiting AUS 1
NCT05665530 Phase I PRT2527 A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies Recruiting USA | POL | ITA | GBR | FRA | DEU | CHE | CAN | AUS 1
NCT05702853 Phase Ib/II CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL Recruiting USA 0
NCT05753501 Phase I ABBV-101 Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies Recruiting USA | ISR | GBR | FRA | ESP | DEU | CAN 1
NCT05773040 Phase I JV-213 A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas Active, not recruiting USA 0
NCT05780034 Phase I AC0676 A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies Recruiting USA 0
NCT05788289 Phase II Lenalidomide + Tafasitamab-cxix A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma Terminated USA 0
NCT05797233 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies Active, not recruiting USA 0
NCT05798897 Phase I MT-601 Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO) Recruiting USA 0
NCT05801913 Phase I CMV-CD19 CAR T-cells + Multi-antigen CMV-modified vaccinia Ankara vaccine Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT05833763 Phase II Glofitamab-gxbm Glofitamab-gxbm + Pirtobrutinib Obinutuzumab A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. (GOlDiLOX) Recruiting AUS 0
NCT05861050 Phase Ib/II Glofitamab-gxbm + Lenalidomide + Obinutuzumab + Venetoclax Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma Recruiting USA 0
NCT05864742 Phase II Ibrutinib + Rituximab + Venetoclax Ibrutinib + Navitoclax + Rituximab + Venetoclax Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (+/-Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma Active, not recruiting AUS 0
NCT05868395 Phase II Bendamustine + Polatuzumab vedotin-piiq + Rituximab Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma Recruiting AUT 0
NCT05878184 Phase I Cyclophosphamide + Fludarabine SC291 Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) Active, not recruiting USA | AUS 0
NCT05879744 Phase I CLN-978 A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) Active, not recruiting USA 0
NCT05910801 Phase II Lenalidomide + Tafasitamab-cxix + Venetoclax Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (V-MIND) Recruiting USA 0
NCT05934838 Phase I Tazemetostat A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas Recruiting USA 0
NCT05950165 Phase Ib/II CHO-H01 + Lenalidomide CHO-H01 A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma Recruiting USA 1
NCT05951959 Phase II Acalabrutinib + Rituximab + Venetoclax A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse) Active, not recruiting USA | POL | GBR | ESP | CAN | BRA | AUS 0
NCT05967416 Phase I SIRPant-M Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma Recruiting USA 0
NCT05976763 Phase III Zanubrutinib Rituximab + Zanubrutinib Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Recruiting USA 0
NCT05989204 Phase I HuCART19-IL18 TmCD19-IL18 in CD19+ Cancers Recruiting USA 0
NCT06014762 Phase I P-CD19CD20-ALLO1 P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies Recruiting USA 0
NCT06026319 Phase I CD79b-19 CAR T cells Cyclophosphamide + Fludarabine CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma Recruiting USA 0
NCT06029309 Phase Ib/II Tafasitamab-cxix + Zanubrutinib Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma (ZANU-TAFA) Recruiting USA 0
NCT06054776 Phase II Acalabrutinib + Glofitamab-gxbm + Obinutuzumab Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Recruiting USA 0
NCT06084936 Phase III Obinutuzumab Glofitamab-gxbm Lenalidomide + Rituximab Bendamustine + Rituximab A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE) Recruiting USA | SWE | ITA | GBR | FRA | ESP | CAN | BRA | AUS 3
NCT06088654 Phase Ib/II IPH6501 Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma Recruiting USA | FRA | AUS 0
NCT06132503 Phase I LP-284 A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors Recruiting USA 0
NCT06191887 Phase I Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Recruiting USA 0
NCT06192888 Phase I Glofitamab-gxbm + Lenalidomide + Obinutuzumab A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma Recruiting USA 0
NCT06208735 Phase I CLIC-2201 CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies Not yet recruiting CAN 0
NCT06252675 Phase II Glofitamab-gxbm + Obinutuzumab + Pirtobrutinib Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma Suspended USA 0
NCT06256484 Phase I ATA3219 A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Recruiting USA | AUS 0
NCT06263491 Phase II Pirtobrutinib + Rituximab Rituximab Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients Recruiting USA 0
NCT06285422 Phase I Cyclophosphamide + Fludarabine SC262 Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) Recruiting USA 0
NCT06300528 Phase II Pemigatinib Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma Not yet recruiting USA 0
NCT06340737 Phase I Anti-CD22 CAR T cells AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas Recruiting USA 0
NCT06343311 Phase Ib/II EB103 T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (STARLIGHT-1) Recruiting USA 0
NCT06343376 Phase I EGFRt/19-28z/IL-12 CAR-T cells Cyclophosphamide + Fludarabine Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Recruiting USA 0
NCT06357676 Phase Ib/II Glofitamab-gxbm + Ibrutinib + Obinutuzumab Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma Not yet recruiting USA 0
NCT06378190 Phase Ib/II TranspoCART19 Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19) Recruiting ESP 0
NCT06392477 Phase I DR-0201 A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Recruiting AUS 5
NCT06482684 Phase II Ibrutinib Ibrutinib + Rituximab Bendamustine + Ibrutinib + Rituximab Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate Brexucabtagene autoleucel Cisplatin + Cytarabine + Dexamethasone + Rituximab CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma (CARMAN) Recruiting DEU 0
NCT06484920 Phase II Pembrolizumab + Tretinoin A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL Recruiting USA 0
NCT06492304 Phase Ib/II CTX131 A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies Recruiting USA 0
NCT06522386 Phase II Pirtobrutinib + Rituximab + Venetoclax GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma Not yet recruiting USA 0
NCT06542250 Phase Ib/II AZD5492 A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. (TITANium) Recruiting USA | ITA | FRA | ESP | DNK | DEU | CAN | AUS 2
NCT06553872 Phase II Brexucabtagene autoleucel Brexucabtagene autoleucel + Pirtobrutinib Pirtobrutinib Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL Recruiting USA 0
NCT06558604 Phase II Glofitamab-gxbm + Obinutuzumab + Venetoclax + Zanubrutinib Glofitamab-gxbm + Obinutuzumab + Venetoclax A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma (GLOASIS) Not yet recruiting FRA | BEL 0
NCT06561425 Phase Ib/II GLPG5101 A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma (Atalanta-1) Recruiting USA | NLD | BEL 0
NCT06572618 Phase II ARQ 531 + Rituximab Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma Not yet recruiting USA 0
NCT06675123 Phase I Acalabrutinib + Pacritinib Pacritinib + Zanubrutinib Ibrutinib + Pacritinib Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Not yet recruiting USA 0